← Back to Screener
Immuneering Corporation Class A Common Stock (IMRX)
Price$5.57
Favorite Metrics
Price vs S&P 500 (26W)-15.52%
Price vs S&P 500 (4W)14.47%
Market Capitalization$371.75M
All Metrics
Book Value / Share (Quarterly)$3.38
P/TBV (Annual)1.95x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.70
Price vs S&P 500 (YTD)-15.26%
Gross Margin (TTM)28.00%
Net Profit Margin (TTM)-9610.00%
EPS (TTM)$-1.38
10-Day Avg Trading Volume0.74M
EPS Excl Extra (TTM)$-1.38
EPS (Annual)$-2.03
ROI (Annual)-147.39%
Gross Margin (Annual)50.00%
Cash / Share (Quarterly)$2.67
ROA (Last FY)-115.72%
EBITD / Share (TTM)$-1.34
ROE (5Y Avg)-64.35%
Operating Margin (TTM)-9778.00%
Cash Flow / Share (Annual)$-1.77
P/B Ratio1.70x
P/B Ratio (Quarterly)1.94x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)486.22x
Net Interest Coverage (TTM)-25.59x
ROA (TTM)-39.75%
EPS Incl Extra (Annual)$-2.03
Current Ratio (Annual)17.50x
Quick Ratio (Quarterly)17.16x
3-Month Avg Trading Volume1.48M
52-Week Price Return342.31%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.37
P/S Ratio (Annual)1161.73x
Asset Turnover (Annual)0.00x
52-Week High$10.08
EPS Excl Extra (Annual)$-2.03
CapEx CAGR (5Y)23.25%
26-Week Price Return-11.54%
Quick Ratio (Annual)17.16x
13-Week Price Return36.26%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)17.50x
Enterprise Value$243.109
Asset Turnover (TTM)0.00x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-15784.38%
Cash / Share (Annual)$1.16
3-Month Return Std Dev63.54%
Net Income / Employee (TTM)$-1
ROE (Last FY)-147.39%
EPS Basic Excl Extra (Annual)$-2.03
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.38
Receivables Turnover (Annual)3.20x
ROI (TTM)-43.33%
P/S Ratio (TTM)743.51x
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.32
Price vs S&P 500 (52W)312.48%
Year-to-Date Return-12.61%
5-Day Price Return1.59%
EPS Normalized (Annual)$-2.03
ROA (5Y Avg)-54.72%
Net Profit Margin (Annual)-15784.38%
Month-to-Date Return9.11%
Cash Flow / Share (TTM)$-1.85
EBITD / Share (Annual)$-2.02
Operating Margin (Annual)-16168.75%
ROI (5Y Avg)-64.35%
EPS Basic Excl Extra (TTM)$-1.38
P/TBV (Quarterly)1.95x
P/B Ratio (Annual)1.94x
Pretax Margin (TTM)-9672.00%
Book Value / Share (Annual)$1.33
Price vs S&P 500 (13W)35.57%
Beta0.34x
Revenue / Share (TTM)$0.00
ROE (TTM)-43.33%
52-Week Low$1.10
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.25
4.25
4.25
4.25
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
IMRXImmuneering Corporation Class A Common Stock | 743.51x | — | 28.00% | — | $5.57 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Immuneering is a biopharmaceutical company developing oncology and neurology treatments using its proprietary Disease Cancelling Technology platform, which leverages computational biology and translational bioinformatics. The company generates revenue from both internal drug discovery programs and by licensing its computational capabilities to other pharmaceutical and biotechnology companies.